NeuraLace Medical - About the company
NeuraLace Medical is a seed company based in San Diego (United States), founded in 2016. It operates as a Non-invasive neuromodulation for chronic neuropathic pain relief and improved patient outcomes. NeuraLace Medical has raised $5.85M in funding from FusionX Ventures. The company has 54 active competitors, including 4 funded and 4 that have exited. Its top competitors include companies like SPR, Remedee Labs and Neurometrix.
Company Details
Non-invasive neuromodulation for chronic neuropathic pain relief and improved patient outcomes. They are focused on revolutionizing chronic pain management through its electroceutical platform, offering a non-invasive alternative to traditional methods. Their Axon Therapy mPNS technology uses magnetic peripheral nerve stimulation to recondition the central nervous system, providing long-term relief from post-trauma and post-surgical neuropathic pain. This innovative approach minimizes dependence on opioids and other medications, improving patients' quality of life. The company's technology is FDA-cleared and supported by clinical trial results, demonstrating significant effects in pain reduction. They are dedicated to freeing the world from chronic neuropathic suffering through advanced neuromodulation technology.
- Website
- neuralacemedical.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2016
Location
San Diego, United States
Stage
Seed
Total Funding
$5.85M in 2 rounds
Latest Funding Round
Investors
Ranked
3rd among 54 active competitors
Employee Count
25 as on Sep 30, 2026
Legal entities associated with NeuraLace Medical
NeuraLace Medical is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Neuralace Medical, Inc. CIN: 6131612 , United States, Active | Aug 23, 2016 | - | - | - |
NEURALACE MEDICAL INC. CIN: 32090307656 , United States, Active | Jun 13, 2023 | - | - | - |
Sign up to download NeuraLace Medical's company profile
NeuraLace Medical's funding and investors
NeuraLace Medical has raised a total funding of $5.85M over 2 rounds. Its first funding round was on Mar 15, 2017. Its latest funding round was a Seed round on Jun 19, 2019 for $*****. 4 investors participated in its latest round. NeuraLace Medical has 9 institutional investors.
Here is the list of recent funding rounds of NeuraLace Medical:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 19, 2019 | 8745218 | Seed | 8858632 | 1328920 | 3956857 | 4938580 |
Mar 15, 2017 | 2811062 | Seed | 6469434 | 7044745 |
View details of NeuraLace Medical's funding rounds and investors
NeuraLace Medical's founders and board of directors
Founder? Claim ProfileNeuraLace Medical's employee count trend
NeuraLace Medical has 25 employees as of Sep 26. Here is NeuraLace Medical's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
NeuraLace Medical's Competitors and alternates
Top competitors of NeuraLace Medical include SPR, Remedee Labs and Neurometrix. Here is the list of Top 10 competitors of NeuraLace Medical, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | SPR 2008, Cleveland (United States), Acquired | Developer of non-implant peripheral nerve stimulation systems for pain management | $132M | 55/100 | |
2nd | Remedee Labs 2016, Meylan (France), Series A | Developer of endorphin stimulation therapy for pain management | $27.8M | 43/100 | |
3rd | NeuraLace Medical 2016, San Diego (United States), Seed | Non-invasive neuromodulation for chronic neuropathic pain relief and improved patient outcomes | $5.85M | 43/100 | |
4th | Neurometrix 1996, Woburn (United States), Acquired | Developer of non-invasive medical devices for pain and neurological disorders | $14.6M | 38/100 | |
5th | Electromedical Technologies 2007, Phoenix (United States), Public | An electrotherapy device that helps reduce and eliminate chronic or acute pain | $105K | 38/100 | |
6th | iTENS 1999, Akron (United States), Unfunded | Wireless pain relief device merging technology with TENS therapy | - | - | 38/100 |
7th | Terapio 2005, Austin (United States), Series A | Medical devices providing TENS therapy for pain relief and muscle stimulation | $9.9M | 37/100 | |
8th | Developer of pain management devices | $4.58M | 33/100 | ||
9th | Hollywog 2009, Chattanooga (United States), Unfunded | Pain relief solutions: TENS units, gel pads, and accessories | - | - | 33/100 |
10th | ReBuilder Medical 2001, Charles Town (United States), Unfunded | ReBuilder Medical: Drug-free pain relief, nerve health restoration solutions | - | - | 32/100 |
Looking for more details on NeuraLace Medical's competitors? Click here to see the top ones
NeuraLace Medical's Investments and acquisitions
NeuraLace Medical has made no investments or acquisitions yet.
Reports related to NeuraLace Medical
Here is the latest report on NeuraLace Medical's sector:
News related to NeuraLace Medical
•
Neuralace's Axon Therapy Gets FDA Nod for Painful Diabetic NeuropathyMedical Product Outsourcing•Jan 11, 2024•NeuraLace Medical
•
Neuralace Medical Announces Clinical Milestones Including Presentation of the Safety and Efficacy of Axon Therapy (SEAT) Study at the American Society of Pain and Neuroscience Conference (ASPN), While Completing Enrollment in the Axon Therapy Painful Diabetic Neuropathy Study (AT-PDN) and Launching a Pilot Study Focused on the Treatment of Chemotherapy Induced Peripheral Neuropathy (CIPN)Tullahoma News•May 30, 2023•NeuraLace Medical
•
Dr Peter Staats, Chief Medical Officer at National Spine and Pain, Joins the Neuralace Medical Advisory BoardMedical Device News•May 25, 2023•NeuraLace Medical, National Spine & Pain Centers
•
•
Neuralace Medical Announces First Patients Enrolled in the AT-PDN Study Evaluating Axon Therapy® for the Treatment of Painful Diabetic NeuropathyPR Newswire•Jan 09, 2023•NeuraLace Medical
•
Neuralace Medical Advises the AMA Issues Unique Category III CPT Code for Transcutaneous Magnetic Nerve StimulationMedical Device News•Jun 29, 2022•NeuraLace Medical
•
NeuraLace Medical Announces Appointment of Keith Warner as Chief Executive OfficerPR Newswire•Mar 26, 2022•NeuraLace Medical, ensoetm.com
•
NeuraLace ties up FDA clearance for chronic pain-relieving nerve stimulation deviceFierce Biotech•Jun 21, 2021•NeuraLace Medical, FDA
•
NeuraLace Medical Receives FDA 510(k) Clearance and U.S. Launch of Axon Therapy® Peripheral Nerve Stimulation SystemMedical Device News•Jun 17, 2021•NeuraLace Medical
•
NeuraLace Medical Closes $3 Million Seed RoundSan Diego Business Journal•Jun 16, 2019•NeuraLace Medical
Are you a Founder ?
FAQs about NeuraLace Medical
Explore our recently published companies
- NADINE BURKE - Germany based, 2005 founded, Unfunded company
- Cell Construction - San Diego based, 2016 founded, Unfunded company
- Start Fresh Ventures - Buffalo based, Unfunded company
- Spirited Resilience - Unfunded company
- Nashville Stock - Unfunded company
- WCG Creative Group - Unfunded company